Key Takeaways Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the ...

Of the two news items, the buyout one had the bigger impact. On Monday, the Financial Times reported in separate articles ...

Bausch & Lomb (NYSE:BLCO) jumped 9% in premarket trading on a report that private equity firms TPG (TPG) and Blackstone (BX) ...

Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...

Bausch Health Companies Inc. ( NYSE:BHC ) shareholders should be happy to see the share price up 26% in the last ...

Shares in Bausch + Lomb were higher after the company received approval from the Food and Drug Administration for its enVista Envy full range of vision intraocular lens. Shares were recently up 23% at ...

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

Bausch + Lomb Corp. (BLCO, BLCO.TO) announced that the U.S. Food and Drug Administration has approved the enVista Envy full range of ...

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

One Bloomberg estimate projected the sale to value Bausch + Lomb at over $13 billion, making the deal potentially one of the ...

Bausch + Lomb receives US FDA approval for enVista Envy full range of vision intraocular lens: Vaughan, Ontario Tuesday, October 15, 2024, 17:00 Hrs [IST] Bausch + Lomb Corporatio ...

Bausch + Lomb said enVista Envy intraocular lenses will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. The company is in the process of seeking ...